Starting too aggressively can increase the likelihood of side effects, while increasing too slowly may delay results for patients who need stronger metabolic support
Studies are also underway for a spectrum of other conditions, including Phase 3 trials investigating non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), and obstructive sleep apnea (OSA), as well as mid-to-late stage trials exploring potential benefits in neurodegenerative disorders like Parkinsons disease
Though both metformin and liraglutide contributed to euglycemia in experimental T2DM of rats, only liraglutide alleviated cerebral injury caused by stroke when compared with metformin
Coronary artery disease (CAD) led at 40.3% of the deaths attributable to CVD, followed by stroke, other minor CVD causes, high blood pressure, heart failure, and peripheral arterial disease [1]
But clinical trial averages don't predict your personal outcome, and results from FDA-approved formulations in controlled trials don't certify identical performance from a compounded formulation
The cells are enhanced to recognize EBV and expanded to produce thousands of doses from a single donor
